Biological evaluation of 2-fluoro-2-[123I]iodo-mannose (FIM): biological evaluation of FIM

G Matte1, M Adam, D Lyster

  • 1Medical imaging, Dalhousie University, Halifax, Canada.

Insights

123I-2-fluoro-2-iodo-mannose (FIM) showed rapid blood clearance and deiodination in mice, unlike 18F-FDG and 18F-DFDG. This radioiodinated mannose analog is not a suitable metabolic marker for in-vivo SPECT imaging.

Area of Science:

  • Nuclear medicine
  • Radiochemistry
  • Biomedical imaging

Background:

  • Fluorodeoxyglucose (FDG) is a widely used PET imaging agent.
  • Development of novel radiotracers for SPECT imaging is crucial for broader clinical application.
  • 123I-labeled compounds offer advantages for SPECT due to their favorable gamma emission properties.

Purpose of the Study:

  • To evaluate 123I-2-fluoro-2-iodo-mannose (FIM) as a potential SPECT imaging agent.
  • To compare the biodistribution of 123I-FIM with established PET agents 18F-FDG and 18F-DFDG.
  • To determine if 123I-FIM can serve as a metabolic marker in vivo.

Main Methods:

  • Radioiodination of 2-fluoro-2-iodo-mannose to produce 123I-FIM.
  • In vitro stability assessment of 123I-FIM.
  • Biodistribution studies of 123I-FIM in mice.
  • Comparison of biodistribution data with published data for 18F-FDG and 18F-DFDG.

Main Results:

  • 123I-FIM demonstrated in vitro stability for 24 hours.
  • Mice exhibited rapid blood clearance and significant deiodination of 123I-FIM.
  • High uptake was observed in the stomach and thyroid, indicating deiodination.
  • Biodistribution of 123I-FIM significantly differed from that of 18F-FDG and 18F-DFDG.
  • 123I-FIM did not function as a metabolic marker in vivo.

Conclusions:

  • 123I-FIM is unstable in vivo, undergoing rapid deiodination.
  • The biodistribution pattern of 123I-FIM is not comparable to 18F-FDG or 18F-DFDG.
  • 123I-FIM is not a suitable radiotracer for in vivo metabolic imaging via SPECT.